Orexo AB (ORX) - Total Assets

Latest as of March 2026: Skr610.40 Million SEK ≈ $65.69 Million USD

Based on the latest financial reports, Orexo AB (ORX) holds total assets worth Skr610.40 Million SEK (≈ $65.69 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Orexo AB (ORX) cash flow to debt to assess how comfortably operating cash covers total debt obligations.

Orexo AB - Total Assets Trend (2002–2025)

This chart illustrates how Orexo AB's total assets have evolved over time, based on quarterly financial data. See Orexo AB shareholders equity for net asset value and shareholders' equity analysis.

Orexo AB - Asset Composition Analysis

Current Asset Composition (December 2025)

Orexo AB's total assets of Skr610.40 Million consist of 89.4% current assets and 10.6% non-current assets.

Asset Category	Amount (SEK)	% of Total Assets
Cash & Equivalents	Skr0.00	70.0%
Accounts Receivable	Skr237.40 Million	18.2%
Inventory	Skr0.00	0.0%
Property, Plant & Equipment	Skr56.40 Million	4.3%
Intangible Assets	Skr400.00K	0.0%
Goodwill	Skr0.00	0.0%

Asset Composition Trend (2002–2025)

This chart illustrates how Orexo AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Orexo AB.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Orexo AB's current assets represent 89.4% of total assets in 2025, an increase from 61.1% in 2002.
Cash Position: Cash and equivalents constituted 70.0% of total assets in 2025, up from 44.7% in 2002.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 29.0% in 2002.
Asset Diversification: The largest asset category is accounts receivable at 18.2% of total assets.

Orexo AB Competitors by Total Assets

Key competitors of Orexo AB based on total assets are shown below.

Company	Country	Total Assets
Takeda Pharmaceutical Company Limited F:TKDA	Germany	€15.41 Trillion
Shandong Buchang Pharmaceuticals Co Ltd SHG:603858	China	CN¥19.57 Billion
Beijing Sun Novo Pharmaceutical Research Co Ltd SHG:688621	China	CN¥2.30 Billion
Guizhou Xinbang Pharmaceutical Co Ltd SHE:002390	China	CN¥8.59 Billion
Guangdong Lifestrong Pharmacy Co. Ltd. SHE:301111	China	CN¥925.41 Million
Jw Pharmac KO:001060	Korea	₩605.27 Billion
Kamada TA:KMDA	Israel	ILA377.21 Million
Samjin Pharm KO:005500	Korea	₩449.14 Billion

Orexo AB - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	2.03	1.73	2.77
Quick Ratio	2.03	1.55	2.49
Cash Ratio	0.00	0.00	0.00
Working Capital	Skr241.10 Million	Skr150.20 Million	Skr603.60 Million

Orexo AB - Advanced Valuation Insights

This section examines the relationship between Orexo AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	2.19
Latest Market Cap to Assets Ratio	0.04
Asset Growth Rate (YoY)	119.0%
Total Assets	Skr1.30 Billion
Market Capitalization	$54.74 Million USD

Valuation Analysis

Below Book Valuation: The market values Orexo AB's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.

Rapid Asset Growth: Orexo AB's assets grew by 119.0% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Orexo AB (2002–2025)

The table below shows the annual total assets of Orexo AB from 2002 to 2025.

Year	Total Assets	Change
2025-12-31	Skr1.30 Billion ≈ $140.20 Million	+119.03%
2024-12-31	Skr594.80 Million ≈ $64.01 Million	-24.38%
2023-12-31	Skr786.60 Million ≈ $84.65 Million	-29.07%
2022-12-31	Skr1.11 Billion ≈ $119.35 Million	-12.93%
2021-12-31	Skr1.27 Billion ≈ $137.07 Million	+3.31%
2020-12-31	Skr1.23 Billion ≈ $132.68 Million	-17.87%
2019-12-31	Skr1.50 Billion ≈ $161.54 Million	+16.66%
2018-12-31	Skr1.29 Billion ≈ $138.47 Million	+28.17%
2017-12-31	Skr1.00 Billion ≈ $108.04 Million	-1.46%
2016-12-31	Skr1.02 Billion ≈ $109.64 Million	+0.25%
2015-12-31	Skr1.02 Billion ≈ $109.37 Million	-17.10%
2014-12-31	Skr1.23 Billion ≈ $131.92 Million	+58.73%
2013-12-31	Skr772.33 Million ≈ $83.12 Million	+60.32%
2012-12-31	Skr481.75 Million ≈ $51.84 Million	-11.78%
2011-12-31	Skr546.10 Million ≈ $58.77 Million	-23.37%
2010-12-31	Skr712.69 Million ≈ $76.70 Million	+9.76%
2009-12-31	Skr649.33 Million ≈ $69.88 Million	-7.51%
2008-12-31	Skr702.02 Million ≈ $75.55 Million	-12.45%
2007-12-31	Skr801.87 Million ≈ $86.29 Million	+111.06%
2006-12-31	Skr379.93 Million ≈ $40.89 Million	+2.32%
2005-12-31	Skr371.31 Million ≈ $39.96 Million	+250.24%
2004-12-31	Skr106.02 Million ≈ $11.41 Million	+134.80%
2003-12-31	Skr45.15 Million ≈ $4.86 Million	+35.80%
2002-12-31	Skr33.25 Million ≈ $3.58 Million	--

About Orexo AB

ST:ORX Sweden Drug Manufacturers - Specialty & Generic

Market Cap

$54.74 Million

Skr508.64 Million SEK

Market Cap Rank

#21499 Global

#398 in Sweden

Share Price

Skr14.48

Change (1 day)

-1.50%

52-Week Range

Skr14.36 - Skr41.60

All Time High

Skr85.70